Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
August 5, 2008

Regeneron to Receive $21.5M from Sanofi-Aventis for VelociGene Animal Models

  • Sanofi-aventis will use Regeneron Pharmaceuticals’ VelociGene platform for genetically modified mammalian models of gene function and disease. Sanofi-aventis will pay a minimum of $4.3 million annually for five years for knock-out and transgenic models of gene function for target genes identified by sanofi-aventis. Sanofi-aventis will use these models for its internal research programs, outside the scope of its antibody collaboration with Regeneron.